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Abstract
Safe and effective treatment options for acne vulgaris are needed to address side effects and
increasing rates of antibiotic resistance from current treatments. Nicotinamide is a vitamin
with potent anti-inflammatory properties that could offer a potential treatment option. We
aim to summarize the relevant literature on the role of nicotinamide in acne vulgaris and dis-
cuss the next steps necessary to move this approach into clinical practice. We searched
PubMed for clinical studies using nicotinamide for treatment of acne vulgaris. We summar-
ized the 10 studies that met our search criteria. Six of eight studies using topical
nicotinamide led to a significant reduction in acne compared with the patient’s baseline or
performed similarly to another standard-of-care acne treatment. Both studies using an oral
supplement containing nicotinamide resulted in a significant reduction in acne compared
with baseline. No major adverse side effects were noted. Our review suggests that topical
and oral nicotinamide has an unclear effect on acne vulgaris due to the limited nature of the
available literature. Additional studies are needed comparing nicotinamide to other first-line
acne treatments and evaluating the efficacy and side effect profile of nicotinamide over an
extended period of time.
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1 | INTRODUCTION
Acne vulgaris is an extremely common chronic inflammatory dis-
ease of the skin that occurs in approximately 80% of young adults
and adolescents, though it can occur in all ages (Fox, Csongradi,
Aucamp, du Plessis, & Gerber, 2016). While the pathogenesis of
acne vulgaris is complex, the basic physiology is widely accepted.
Hypercornification combined with excess sebum production pro-
vokes clogging of the pores (Toyoda & Morohashi, 2001). Propiono-
bacterium acnes (P. acnes) proliferate in this environment and cause
an increase in inflammatory cytokines and free fatty acids, which
then leads to further irritation (Muizzuddin, Giacomoni, & Maes,
2008). Studies suggest genetic, neuroendocrine, and dietary factors
may also contribute to the multifactorial process of acne vulgaris
pathogenesis (Zaenglein et al., 2016).
Treatments for acne vulgaris target one or more of the steps in
pathogenesis and may be administered topically or orally. The most
widely used acne treatments are topical formulations. Common exam-
ples include retinoids, antibiotics, antibacterial agents, and comedolytic
agents (Fox et al., 2016). Systemic treatments are used for more severe
or resistant forms of acne, including oral isotretinoin, oral antibiotics,
and hormonal agents (Katsambas & Papakonstantinou, 2004). These
treatment modalities are not without their drawbacks. Topical retinoid
use may be limited by dryness, erythema, and irritation, while oral iso-
tretinoin treatment is teratogenic and requires routine monitoring of
serum lipid profiles and liver function tests (McElwee et al., 1991). Top-
ical and oral antibiotic overuse and resistance are a growing global con-
cern, both for the effectiveness of acne therapies and for the
treatment of infectious diseases (Humphrey, 2012; Ventola, 2015).
Many countries have reported that over 50% of P. acnes strains are
antibiotic resistant, particularly to topical macrolides (Walsh, Efthimiou,
Abbreviations: g, grams; mg, milligrams; mcg, micrograms; P. acnes,
Propionibacterium acnes; NAD, nicotinamide adenine dinucleotide; NADP,
nicotinamide adenine dinucleotide phosphate; PARP-1, poly-ADP-ribose
polymerase-1.
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& Dreno, 2016). Regarding the use of hormonal modulators, venous
thromboembolism risk remains a concern. For these reasons, alterna-
tive treatments have entered the arena of acne care.
Nicotinamide provides potent anti-inflammatory properties
without the risk of bacterial resistance and systemic side effects
and represents a potential treatment modality for acne vulgaris. Nic-
otinamide, also known as niacinamide, is a form of vitamin B3,
which is an essential water-soluble nutrient present in a variety of
foods. Nicotinamide is the amide form of nicotinic acid (niacin) and
is identical in vitamin function; however, it does not carry the same
vasodilatory, hypolipidemic, and gastrointestinal actions (Knip et al.,
2000). Furthermore, nicotinamide has demonstrated a low incidence
of side effects and toxicity at oral doses up to 3 g per day for up to
5 years (Knip et al., 2000). Nicotinamide is a precursor for nicotina-
mide adenine dinucleotide (NAD) and the phosphorylated derivative
NADP (Hoffer, 1967). NAD provides a substrate for nuclear enzyme
poly-ADP-ribose polymerase (PARP-1), which repairs damage from
genotoxic stresses, such as UV radiation (Park, Halliday, Surjana, &
Damian, 2010; Surjana, Halliday, & Damian, 2010). Having adequate
cellular energy and properly functioning PARP-1 is important for a
number of skin conditions, for which nicotinamide may have benefi-
cial effects (Chen et al., 2015).
Nicotinamide appears to play a number of potential roles in the
treatment of acne vulgaris. Draelos et al. demonstrated that 2% topical
nicotinamide resulted in a significant reduction in sebum excretion rate
in a Japanese study group and decreased casual sebum levels (sebum
on the skin surface) in a Caucasian study group over 4 weeks (Draelos,
Matsubara, & Smiles, 2006). In addition, topical nicotinamide helps pro-
tect the natural barrier of the skin against infection and may have a
bacteriostatic effect on P. acnes (Fivenson, 2006; Wohlrab & Kreft,
2014). Finally, nicotinamide decreases the in vitro secretion of
interleukin-8, a cytokine secreted by keratinocytes in response to
pathogens (including P. acnes), thereby exerting an anti-inflammatory
effect through inhibition of leukocyte chemotaxis (Grange, Raingeaud,
Calvez, & Dupin, 2009). Additional anti-inflammatory action may occur
via inhibition of lysosomal enzyme release and mast cell degranulation
(Wohlrab & Kreft, 2014).
Nicotinamide for use in dermatologic ailments has shown promise
in clinical studies but has not yet become a standard treatment option.
This review examines the potential role of nicotinamide in acne vulga-
ris, summarizes the relevant published articles, and discusses what
studies are needed to move this new approach to such a common ail-
ment into widespread clinical practice.
2 | METHODS
We searched PubMed for all articles in English with the following
words in the title or abstract: “acne,” “nicotinamide,” “niacinamide,” and
“vitamin B3” with no restriction on dates up to October 2016. This
search yielded 41 articles. Two reviewers independently determined
the eligibility of the studies and performed the methodological quality
assessment.
Inclusion Criteria:
 Studies must directly involve subjects with at least mild acne
 Studies must use a human model
 Studies must use topical and/or oral nicotinamide treatments
For each experiment, we determined the degree of acne vulgaris, treat-
ment group regimen, control group regimen, duration of treatment, out-
come measures, and results. Treatments containing only nicotinamide are
referred to as “single-agent products,” whereas treatments containing nic-
otinamide in addition to other components are referred to as “combina-
tion products.” Quantitative assessment of acne lesions involved counts
of comedones, papules/pustules, and/or cysts. Qualitative assessment of
acne lesions was based on the Physician’s Global Evaluation of Inflamma-
tory Acne or modifications of Cook’s Acne Grade. The Physician’s Global
Evaluation of Inflammatory Acne involves rating the change in acne on a
scale from “much better” to “worse.” Cook’s Acne Grade involves rating
acne based on how much of the face is involved. We summarized our
findings and determined what essential information is missing from the
literature, and thus, should be studied before nicotinamide can make its
way into standard clinical treatment of acne vulgaris.
3 | RESULTS
Ten articles matched our search criteria; all studies tested the efficacy
of nicotinamide on acne vulgaris in humans using either topical or oral
therapies. The design and results of the studies are summarized in
Tables 1–3. Eight out of the 10 studies demonstrated a significant
reduction in acne lesions compared with the patient’s baseline acne or
similar efficacy to a commonly used treatment for acne vulgaris. Four
of the studies used nicotinamide as a single-agent topical product; four
of the studies used nicotinamide as a combination topical product; and
two of the studies used an oral form of nicotinamide. Outcomes of the
available research for each study design are summarized below.
3.1 | Single-agent topical products
Four studies used nicotinamide as a single-agent topical product
(Table 1). Three of the studies randomized patients to treatment with
nicotinamide only or clindamycin only; all three studies found that the
nicotinamide group had significantly improved acne vulgaris from base-
line and that nicotinamide and clindamycin resulted in similar reduc-
tions in acne lesions (Khodaeiani, Fouladi, Amirnia, Saeidi, & Karimi,
2013; Shahmoradi, Iraji, Siadat, & Ghorbaini, 2013; Shalita, Smith, Par-
ish, Sofman, & Chalker, 1995). Kaymak treated all study participants
with only niacinamide and found a significant improvement in acne vul-
garis from baseline (Kaymak, 2008). None of the four studies compared
nicotinamide to a placebo-treated control group.
3.2 | Combination topical products
Four studies used nicotinamide in a combination topical product
(Table 2). Dos et al. and Sardesai and Kambli directly compared a
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combination product containing nicotinamide and clindamycin to a
clindamycin-only treatment group (Dos, Barbhuiya, Jana, & Dey,
2003; Sardesai & Kambli, 2003). Both studies demonstrated a sig-
nificant improvement in acne vulgaris from baseline for both treat-
ment groups, but there was no difference in acne vulgaris when
topical nicotinamide and clindamycin were combined (Dos et al.,
2003; Sardesai & Kambli, 2003). Morganti and colleagues random-
ized patients to receive treatment with emulsions composed of
numerous ingredients and either 4% nicotinamide, 1% clindamycin,
or neither (emulsion vehicle) (Morganti et al., 2011). The nicotina-
mide treatment group quantitatively demonstrated a significant
improvement in acne vulgaris compared with the emulsion contain-
ing clindamycin and the emulsion vehicle (Morganti et al., 2011).
Emanuele compared a nicotinamide treatment group containing 4%
nicotinamide, 1% retinol, and 0.5% 7-dehydrocholesterol to the
patient’s baseline acne (Emanuele, Bertona, Altabas, Altabas, &
Alessandrini, 2012). There was a significant improvement in acne
vulgaris using this treatment compared with the patient’s baseline
(Emanuele et al., 2012). It is unclear if the nicotinamide or the other
ingredients in the combination product were responsible for the
significant improvement.
3.3 | Oral nicotinamide products
Two studies involving oral nicotinamide therapy for acne vulgaris
matched our search criteria (Table 3). Niren and Torok used a com-
bination product containing nicotinamide, zinc, copper, and folic
acid and demonstrated a significant improvement in acne vulgaris
compared with acne prior to treatment (Niren & Torok, 2006).
There was no difference in acne lesions when an oral antibiotic
(name not stated in primary article) was combined with the nicotin-
amide combination product. Shalita et al. used a combination prod-
uct containing nicotinamide, azelaic acid, zinc, pyridoxine, copper,
and folic acid and showed a significant improvement in acne vulga-
ris compared with acne prior to treatment (Shalita et al., 2012).
Participants in this study were permitted to continue their regular
acne regimens during the study; therefore, it is unclear if the treat-
ment was responsible for the improvement in acne vulgaris. In both
studies, the individual components of each combination product
were not tested separately; therefore, it is unclear if nicotinamide
itself contributed to the improvement in acne vulgaris. There were
no studies that tested the effect of oral nicotinamide on acne vul-
garis as a single-agent.
3.4 | Side effects
No major adverse side effects were noted by any of the studies. Minor
side effects for nicotinamide topical treatments included itching, burn-
ing, mild dermatitis, and greasy skin. These side effects were also expe-
rienced by patients in the “other topical treatment” groups with no
significant difference in frequency or severity between groups in any
of the topical studies. No side effects were experienced by patients
taking oral nicotinamide formulations.T
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4 | DISCUSSION
Acne vulgaris remains a prevalent problem, and the need persists for
new safe and effective treatment options. Current modalities carry sig-
nificant risks, including antibiotic resistance and systemic interactions
(Walsh et al., 2016). Unpleasant side effects, such as dry, irritated skin
with topical retinoids or mandatory routine laboratory monitoring with
oral isotretinoin, are not only concerning, but they limit compliance for
many patients. Topical and oral forms of nicotinamide represent a pos-
sible treatment alternative for acne vulgaris, but the benefit of these
products is unclear. Our literature review suggests that a limited series
of studies demonstrate that topical nicotinamide treatments have a sig-
nificant effect on reducing acne vulgaris with minimal side effects. Four
of these studies also showed that topical nicotinamide reduced acne
lesions similarly to topical clindamycin, thereby implying that nicotina-
mide could potentially be used as a treatment alternative to clindamy-
cin. However, two of the eight topical studies showed that
nicotinamide did not demonstrate a reduction in acne lesions when
added to clindamycin treatment. The benefit of oral nicotinamide is fur-
ther unclear because nicotinamide has only been tested as a combina-
tion product and not by itself.
The authors opine that there are several study design limitations
that need to be addressed to determine if nicotinamide is a potential
treatment option for acne vulgaris in the clinical setting. The current lit-
erature would benefit from additional studies using an adequate con-
trol group, expanding comparisons of nicotinamide with other
standard-of-care acne vulgaris treatments, lengthening treatment end-
points, objectifying outcome measures, and establishing a long-term
side effect profile.
4.1 | Control groups
Six of the 10 studies examined combination treatments without includ-
ing a treatment group consisting of only nicotinamide. This design
makes it difficult to determine what product within the combination
treatment is responsible for the effect on acne vulgaris. In addition,
only one study prospectively randomized patients to a control group
that received treatment with a gel containing the active treatment or a
vehicle gel (gel that does not contain active treatment); including such
a control group would clarify if the improvement was due to time or
the treatment itself (Morganti et al., 2011).
4.2 | Additional treatment groups
The American Academy of Dermatology’s treatment algorithm for
acne vulgaris recommends first line treatment for mild acne with
benzoyl peroxide, topical retinoid, or topical combination therapy
(benzoyl peroxide1 antibiotic, retinoid1 benzoyl peroxide, or reti-
noid1benzoyl peroxide1 antibiotic) (Zaenglein et al., 2016). These
agents are often used in the treatment of moderate acne vulgaris as
well. Therefore, there is a need to compare the effects of nicotina-
mide to these first-line products in single treatment and combina-
tion treatment forms. No topical studies compared nicotinamide to
benzoyl peroxide or used a nicotinamide-benzoyl peroxide combina-
tion product. One topical nicotinamide combination product
included retinol but did not directly compare nicotinamide by itself
to a retinoid gel or a vehicle gel. None of the oral nicotinamide stud-
ies compared nicotinamide to systemic antibiotics alone or to oral
isotretinoin.
The optimal concentrations, doses, and treatment regimens have
yet to be determined for topical and oral nicotinamide treatments. Top-
ical nicotinamide gel has shown positive effects on acne vulgaris at 4%
and 5% concentrations. Oral nicotinamide has been used successfully
to treat acne vulgaris at 600 mg and 750 mg nicotinamide one to four
times daily (Niren & Torok, 2006). Further studies are needed to
directly compare different amounts of nicotinamide to obtain a clinical
standard for acne vulgaris treatment.
4.3 | Study length
Only one topical study tested treatment groups for to an endpoint of
12 weeks (Morganti et al., 2011). The other topical studies all used
endpoints ranging from 6 to 8 weeks. Clindamycin was used as a com-
parison group in six out of the eight topical studies; however, the topi-
cal form of this antibiotic is effective at reducing acne lesions over an
8- to 12-week period (Shahlita, Smith, & Bauer, 1984). Combination
products consisting of clindamycin and benzoyl peroxide have shown
significant treatment benefit over an 11-week period, while topical reti-
noids have shown benefit over a 12-week period (Berger et al., 2007;
Jarratt & Brundage, 2012; Lookingbill et al., 1997). Additional studies
with endpoints of at least 12 weeks for nicotinamide treatment are
needed to determine the true efficacy of topical nicotinamide treat-
ment compared with these agents.
Both oral nicotinamide treatments were tested for 8 weeks and
compared with baseline (Niren & Torok, 2006; Shalita et al., 2012).
However, most systemic antibiotics and oral isotretinoin treatments
are given over a course of 3–6 months (Akman et al., 2007; Kus, Yucel-
ten, & Aytug, 2005). Future studies involving oral nicotinamide treat-
ments should consider expanding their treatment course to further
establish long-term effects on acne vulgaris treatment. Additional stud-
ies are needed for both oral and topical treatments that detail efficacy
following cessation of treatment.
4.4 | Outcome measures
Eight of the 10 studies used quantitative outcome measures, but there
was little consistency in the outcome measures used (number of
lesions, scarring, etc.). Although no universal grading scale can be rec-
ommended, using a quantitative grading scale that includes the num-
bers and type of acne lesions, disease severity, and scarring can help
objectively guide treatment over time and compare results between
treatment options (Zaenglein et al., 2016). Improvement in erythema
and reduction in sebum production are additional outcome measures
that could help define responses to nicotinamide treatment (Winston &
Shalita, 1991).
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4.5 | Side effect profile
In this review, no major adverse effects were noted by patients receiv-
ing treatment with nicotinamide; however, longer term studies are
needed to adequately profile side effects of nicotinamide for both topi-
cal and oral agents. Although most patients experience minimal side
effects at topical concentrations less than 6% and oral doses less than
3 g/day, potential severe side effects at high doses include elevation of
liver enzymes, nausea, heartburn, and flushing (Knip et al., 2000).
5 | FUTURE APPLICATIONS
Nicotinamide has shown promise not only in the realm of treating acute
acne vulgaris, but also with respect to complications of acne, including
pigmentation changes. Recent studies have demonstrated that nicotina-
mide has significant skin lightening effects through the inhibition of mel-
anosome transfer from melanocytes to keratinocytes (Hakozaki et al.,
2002). This mechanism of action could benefit patients being treated
for acne who are predisposed to post-inflammatory hyperpigmentation,
but future studies are needed. Furthermore, nicotinamide may not
cause sun-sensitivity that is associated with other lightening agents
used to treat post-inflammatory hyperpigmentation. Rather, nicotina-
mide potentially prevents photoimmunosuppression and photocarcino-
genesis (Chen et al., 2015). These benefits make it a possible adjunct
therapy to existing photosensitizing acne treatments, such as the tetra-
cycline antibiotics or retinoids. Uses of nicotinamide should continue to
be explored through randomized controlled clinical trials as it has the
potential to benefit dermatologic care for multiple indications.
6 | LIMITATIONS OF THIS REVIEW
Our study has several limitations. First, as this is a review article, there is a
potential for publication bias. If only positive studies are published, the
review of the literature will be overwhelmingly positive. This is an inherent
problem for all review articles and could very well be a factor in this
review. However, there has been increasing awareness of this issue, and
many studies with negative results are being published in high impact
journals. Second, our review did not limit our included studies to only
double-blinded randomized-controlled trials due to the lack of such stud-
ies in the literature. Therefore, the results reported in the studies are
more subject to biases and less clearly due to the effects of nicotinamide.
However, the findings by multiple studies that nicotinamide had an equiv-
alent effect as clindamycin certainly supports more thorough investigation
into the treatment potential of nicotinamide. Finally, because only 10
studies met our selection criteria and most of the studies were relatively
small, we may simply not have enough power to demonstrate real differ-
ences between nicotinamide and clindamycin. This further highlights the
need for large, double-blinded, randomized-controlled clinical trials.
7 | CONCLUSION
Nicotinamide is an inexpensive, over-the-counter, water-soluble vita-
min with a well-established safety profile. Limited studies have sug-
gested that it is effective in treating acne vulgaris, but additional
evidence is necessary before nicotinamide can be considered an alter-
native or adjunct to current acne vulgaris treatment regimens. Addi-
tional randomized controlled clinical trials are needed comparing
nicotinamide to other first-line acne treatments and evaluating the effi-
cacy and the side effect profile of nicotinamide over an extended
period of time.
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